NBD-556 is primarily researched for its potential application in antiviral therapy, particularly in the treatment of HIV. It functions as an entry inhibitor, targeting the CD4 binding site on the HIV-1 envelope glycoprotein gp120. By binding to this site, NBD-556 prevents the virus from attaching to and entering human CD4+ T cells, a critical step in the HIV infection process. This mechanism makes it a promising candidate for developing new antiretroviral drugs. Additionally, studies on NBD-556 contribute to a deeper understanding of HIV entry mechanisms, aiding in the design of more effective therapeutic strategies. However, its clinical use is still under investigation, and further research is needed to optimize its efficacy and safety.